The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole

被引：0
|
作者：
Bekkers, CHJ
Touw, DJ
Lamers, CBHW
Geus, WP
机构：
[1] Hague Cent Pharm, The Hague, Netherlands
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Leyenburg Hosp, The Hague, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [21] Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers
    Ko, JW
    Jang, IJ
    Shin, JG
    Nam, SK
    Shin, SG
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) : 606 - 614
  • [22] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [23] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [24] Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
    Pedersen, Rasmus S.
    Noehr-Jensen, Lene
    Brosen, Kim
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (10): : 683 - 688
  • [25] Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent
    He, N
    Huang, SL
    Zhu, RH
    Tan, ZR
    Liu, J
    Zhu, B
    Zhou, HH
    XENOBIOTICA, 2003, 33 (02) : 211 - 221
  • [26] Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
    Sagar, M
    Tybring, G
    Dahl, ML
    Bertilsson, L
    Seensalu, R
    GASTROENTEROLOGY, 2000, 119 (03) : 670 - 676
  • [27] Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects
    Na, Joo Young
    Jeon, Inseung
    Yoon, Jangsoo
    Choi, Yewon
    Yoon, Seo Hyun
    Yu, Kyung-Sang
    Chung, Jae-Yong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (12): : 1469 - 1477
  • [28] Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
    Yasui-Furukori, N
    Takahata, T
    Nakagami, T
    Yoshiya, G
    Inoue, Y
    Kaneko, S
    Tateishi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) : 487 - 494
  • [29] Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism
    Lutz, M
    Schwab, M
    Griese, EU
    Marx, C
    Müller-Oerlinghausen, B
    Schönhöfer, PS
    Meisner, C
    Gleiter, CH
    Eichelbaum, M
    Mörike, K
    PHARMACOGENETICS, 2002, 12 (01): : 73 - 75
  • [30] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
12345